Wall Street Interest In Biotech IPOs May Be Piqued By NDA Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotechs looking to go public could benefit from momentum from positive FDA reviews, Ernst & Young partner predicts.